IMO, the acute respiratory diagnosis will get big market awareness after COVID-19 or maybe we read the market completely wrong and the big revenue will actually be from the chronic respiratory management product.
Ann: Section 708A Notice and Appendix 2A, page-44
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #